Hypermarker

As many research organisations are stepping away from X, Hypermarker has decided to do the same. We will no longer post updates here. Stay informed via: 🌐 hypermarker.eu 🔗 linkedin.com/company/hyperm… Thank you for following us!

📢 The Hypermarker team is gathering for its Annual Meeting next week in Birmingham! 📍 Venue: Birmingham, United Kingdom 📅 Dates: 7–8 May 2025 Looking forward to visiting Birmingham and reconnecting with the consortium in person. #Hypermarker

Meet Alastair Mobley, Trial Team Manager & PhD student at University of Birmingham, designing & delivering randomised clinical trials in #Hypermarker. He explores atrial fibrillation's ties to vascular disease & dementia. Off-duty, he enjoys sports, music, & walking his dog Loki.

We've launched a new News Section on our website. Stay up-to-date with the latest insights and developments from the Hypermarker project. 🌐 Check it out now: hypermarker.eu/news #Hypermarker

Check out this collaborative paper from our team and IMI Trials@Home. Authored by Sam Muller, Tessa van Rijssel, and Ghislaine Van Thiel, the article delves into ethical AI applications in health research. Read more in Drug Discovery Today. 📖🔍 doi.org/10.1016/j.drud…

Last week, a dedicated team of researchers gathered at the Leiden Academic Centre for Drug Research, Leiden University, to discuss the first draft of the Hypermarker hypertension model. This version has been enriched with project data and now reviewed against additional datasets.

Yesterday, we hosted a Patient and Public Involvement & Engagement workshop on personalised hypertension management. Thank you to our partners @UMCU_Intl, @ehnheart , @news_ub, and @MedicineMenNL & to the patients who shared their insights. hypermarker.eu

As we step into 2025, we also embark on the third year of our project. We're looking forward to the discoveries and collaborations that lie ahead. Visit our website to learn more about Hypermarker: hypermarker.eu #Hypermarker

As we near the completion of two years in our project, we're half way through with much achieved and more to explore! The team is looking forward to a well-deserved break over the Christmas period. Wishing everyone a Merry Christmas and a Happy New Year! #Hypermarker

Mai Elkhalek, with a background in Bio Pharmaceutical Sciences, is pursuing her PhD at Leiden University. Her research in Hypermarker aims to develop methods for identifying hypertension biomarkers & optimising patient-specific treatments. A fan of drawing, guitar, and nature.

The first periodic report of Hypermarker has been accepted by our funding agency. Well done team! #Hypermarker

Progress update! We've shipped 800 blood samples from the UCC-Smart cohort to @UniLeidenNews for metabolomic analysis. This effort is key to unlocking new insights in metabolic research. #Hypermarker #Metabolomics

We've shipped 1,000 blood samples from the AlphaOmega study at the University of Wageningen to University of Leiden for metabolomic analysis. This crucial step will enhance our understanding of metabolic profiles. Exciting insights ahead! #Hypermarker #Metabolomics

Wrapped up a fantastic annual meeting at the University Clinic Hamburg-Eppendorf! Here’s a group photo to celebrate our gathering and say hello to our online community. Immense thanks to our hosts for their hospitality, which enabled two days filled with fruitful discussions.

This October 9th-10th, the Hypermarker team is convening for our annual meeting at @UKEHamburg. We’ll be engaging in key discussions on the progress and future plans of our research initiatives. #Hypermarker #AnnualMeeting2024

We've inked the third and last key agreement, allowing us to send samples & data from Wageningen University to @UniLeidenNews, Netherlands, for in-depth metabolomic analysis. Big developments ahead! #Hypermarker #Metabolomics

@amsterdamumc is now officially a partner at Hypermarker. Delighted to continue working with Alicia Uijl, who has been part of our team since last year. Welcome aboard, Amsterdam UMC! #Hypermarker #AmsterdamUMC

As part of the Horizon Europe funding programme, we had the opportunity to present our project's progress to external evaluators today. Hearing their feedback on our advancements was truly insightful. Looking forward to what comes next! #Hypermarker #HorizonEurope

We've submitted our first report detailing our financial expenditure and progress over the first 18 months of Hypermarker to our funding agency. Reporting on how funding has been spent is an integral component of these Horizon Europe projects. #Hypermarker #HorizonEurope

This article in Nature Medicine stems from the EU/EFPIA IMI BigData@Heart that preceded Hypermarker. It demonstrates the potential for augmentation with machine learning technology from the team coordinating analytics for Hypermarker. doi.org/10.1038/s41591…